WebJul 13, 2024 · MorphoSys AG (XTRA:MOR) entered into a definitive agreement to acquire Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST) for $1.6 billion on June 2, 2024. … WebJul 15, 2024 · This communication contains forward-looking statements related to MorphoSys, Constellation, the acquisition of Constellation by MorphoSys and the …
MorphoSys May Not Recover From Adventurous Constellation …
WebMar 14, 2024 · MorphoSys AG Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update. read more. 03/14/2024. WebThe primary endpoint of the study is a 35% or greater reduction in spleen volume (SVR35) from baseline at 24 weeks. The key secondary endpoint of the study is a 50% or greater improvement in total symptom score (TSS50) from baseline at 24 weeks. Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST-2 trial sponsor. cliffside hearth
MorphoSys Partners with Royalty Pharma to Fund $1.7B …
WebThe need for therapies for myelofibrosis (MF) persists, especially in the setting of JAK inhibitor failure. Lysine-specific demethylase-1 (LSD1) is a histone demethylase critical for self-renewal potential of malignant stem cells and progenitor maturation. WebNov 15, 2024 · Study Design: PACIFICA is a multinational, multicenter, randomized, controlled phase 3 trial of pacritinib vs P/C in adults with primary or secondary … WebJun 2, 2024 · MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany … cliffside hardware pull